Biosafety level 2
Morphoplant receives approval to handle microorganisms of biosafety level 2 (BioStoffV).DIN EN ISO 13485:2016 certification
Morphoplant's development process is certified in accordance with the new DIN EN ISO 13485:2016 (Medical devices - Quality management systems - Requirements for regulatory purposes). ISO 13485:2016 as an internationally recognized quality standard requires an organization to demonstrate that it has the comprehensive quality management systems in place to consistently meet the specific customer and regulatory requirements applicable to medical equipment.Revised online shop
The revised online shop is ready in a modern look. Acquire selected growth factors in high quality at reasonable prices. See you at https://growthfactors.de .DIN EN ISO 13485 certification
Morphoplant's development process is certified in accordance with DIN EN ISO 13485 (Medical devices - Quality management systems - Requirements for regulatory purposes). ISO 13485 as an internationally recognized quality standard requires an organization to demonstrate that it has the comprehensive quality management systems in place to consistently meet the specific customer and regulatory requirements applicable to medical equipment.Two new patents have been granted to Morphoplant
After having received European patent (EP 2121058) concerning long-term storage and conservation of ultrahydrophilic implants, Morphoplant has also received patent approval in Australia (AU2011253759). In Japan Morphoplant has been granted a patent (JP559684) concerning the immobilization of growth factors on bone grafting materials. Morphoplant has already received a patent in Australia (AU20088320842) regarding this technology.Recombinant production of stem cell homing factor SDF-1
Morphoplant has built up a process for the recombinant production of SDF-1 (stromal cell-derived factor 1). SDF-1 performs an essential role in cell migration and proliferation as well as in the homing of stem cells. SDF-1 will be immobilized together with BMP-2 and VEGF on bone graft materials to further accellerate new bone formation.Development of BMP-2- and VEGF-PDLLA nano-composites
Electro-spun PDLLA-nanofibers could be functionalized by Morphoplant with BMP-2 and VEGF, either by protein-adsorption to, or by incorporation into electro-spun PDLLA-nanofibers. The resulting 2D fleeces or 3D tubular scaffolds should be suitable to mimic the nature and function of the native extracellular matrix of bone tissue or artificial blood cells.